ENVI opinion signals early resistance to Biotech Act SPC extension
The European Parliament's Environment, Climate and Food Safety Committee (ENVI) has delivered the first parliamentary opinion on the European Commission's proposed Biotech Act
The ENVI Committee position is an early indication of the political battles ahead over the proposed extension of intellectual property incentives for a small number of biotech innovations in the health sector.
While ENVI is not one of the lead committees on the file, responsibility rests primarily with Parliament's Public Health Committee (SANT) and Industry, Research and Energy Committee (ITRE), the opinion adopted under rapporteur Nicolás Casares (S&D, Spain) provides an important signal of the position emerging within the Socialists and Democrats (S&D) group on one of the most contested elements of the proposal: the 12-month extension to Supplementary Protection Certificates (SPCs).
The Commission's Biotech Act seeks to strengthen Europe's competitiveness in biotechnology and life sciences through a package of measures designed to encourage investment, accelerate innovation and improve the translation of scientific breakthroughs into commercial products. One of its most debated provisions is Article 27, which would grant a limited extension of SPCs for certain frontier biotechnology products.
ENVI has now proposed removing Article 27 altogether.
In his report, González Casares argues that the proposed extension lacks sufficient economic justification. He writes that the "proposed extension of supplementary protection mechanisms lacks a proper econometric impact assessment" and questions whether additional exclusivity would effectively address market failures, particularly in the development of veterinary medicinal products.
The report notes that while linking incentives to European production may appear attractive in principle, the economics of zoonotic vaccine development - in particular - are often driven by unpredictable outbreaks and public health emergencies, Casares questions the value of a fixed exclusivity extension in these circumstances.
Instead, ENVI argues that more targeted policy instruments would be better suited to stimulate innovation in this area. The report suggests push incentives such as research grants, public-private partnerships and support for clinical development, alongside pull incentives including advance purchase commitments, market guarantees and strategic procurement mechanisms, could produce better results.
The position has prompted concern from the biotechnology sector, which sees the SPC extension as already quite narrow in scope.
Biotech sector raises concern
Reacting to the ENVI report, EuropaBio Director General Dr Claire Skentelbery described the outcome as "a mixed bag for biotechnology."
"The decision to remove Article 27 on the Supplementary Protection Certificate (SPC) is really concerning for Europe's health biotech sector," she said.
"At a time when the Union must strengthen its innovation base, it risks actively discouraging investment and undermining efforts to anchor innovation here."
Skentelbery stressed that the proposed extension was deliberately limited in scope.
"Let's be really clear, the SPC was very narrowly defined to target frontier biotechnology, breakthroughs that won't see biosimilars any time soon, if ever."
She warned that removing the measure could undermine Europe's position in next-generation medicines and disproportionately affect smaller biotechnology companies.
"This is a risk to EU research excellence in next-generation medicines, especially from smaller innovators who are the ones breaking barriers for medicine," she said.
The debate over the extension is likely to intensify as the proposal moves through Parliament and the Council. While the ENVI opinion focuses heavily on veterinary applications and zoonotic vaccines, the Commission's proposal is primarily aimed at supporting cutting-edge human health biotechnology where development timelines, regulatory uncertainty and investment risks remain exceptionally high.
Catherine Feore
Council starts it examination
Meanwhile, attention is increasingly turning to the Council, where member states are only beginning to examine the Commission Staff Working Document underpinning the proposal. Member states are expected to analyse the Commission's cost estimates in detail before forming positions on the SPC extension.
Several capitals are understood to be seeking a deeper analysis of the potential implications for healthcare budgets, impact on innovation and support for industry before endorsing any additional exclusivity period.
Although ENVI's opinion is non-binding, it offers the first clear parliamentary indication that support for the SPC extension cannot be taken for granted. More importantly, it suggests that opposition within the S&D family may extend to the SANT rapporteur Vytenis Andriukaitis and become a broader political fault line as negotiations on the Biotech Act gather pace.